VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ELAN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ELANElanco Animal Health Incorporated
$26.41$12.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ELAN
  4. Financial Ratios

Elanco Animal Health Incorporated (ELAN) Financial Ratios

Latest Ratios: P/E Ratio -89.1x · EV/EBITDA 15.8x · ROE -3.7%. (2016–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ELAN Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$12.9B$11.2B$6.0B$7.3B$6.0B$13.8B$13.5B$10.9B$9.9B——
Enterprise Value$16.4B$14.7B$9.9B$12.8B$11.5B$19.5B$19.2B$12.9B$11.9B——
P/E Ratio →-89.08—17.81————163.61112.61——
P/S Ratio2.512.381.361.661.352.904.143.553.23——
P/B Ratio1.961.720.991.180.821.841.601.971.90——
P/FCF31.6439.5515.2962.6922.2748.35—408.4428.04——
P/OCF23.0520.0611.1327.0713.2028.63—48.6620.30——

P/E links to full P/E history page with 30-year chart

ELAN EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—3.122.222.892.604.095.864.213.88——
EV / EBITDA15.8315.7810.8212.5110.7519.1343.5518.8819.50——
EV / EBIT65.01—11.94—62.27——82.2882.73——
EV / FCF—51.7825.06109.0442.7568.21—484.1333.70——

ELAN Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin43.5%43.5%43.0%43.9%44.7%43.6%38.1%45.6%42.2%40.6%45.8%
Operating Margin5.3%5.3%5.7%7.4%8.7%6.4%-2.3%12.0%10.2%4.9%9.7%
Net Profit Margin-4.9%-4.9%7.6%-27.9%-1.8%-10.1%-17.1%2.2%2.8%-10.8%-1.6%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-3.7%-3.7%5.5%-18.2%-1.1%-6.0%-8.0%1.3%1.3%-4.2%-0.7%
ROA-1.8%-1.8%2.5%-8.2%-0.5%-2.8%-4.2%0.8%1.0%-3.6%-0.6%
ROIC1.9%1.9%1.7%2.0%2.2%1.7%-0.5%3.8%3.2%1.5%3.1%
ROCE2.2%2.2%2.1%2.4%2.7%2.0%-0.6%4.6%3.9%1.8%3.8%

ELAN Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.610.610.710.930.800.840.720.420.48——
Debt / EBITDA4.314.314.735.665.476.2013.923.444.05——
Net Debt / Equity—0.530.630.870.750.760.660.360.38-0.04-0.04
Net Debt / EBITDA3.733.734.225.325.155.5712.792.953.28-0.70-0.48
Debt / FCF—12.239.7846.3420.4919.86—75.695.66-4.30-5.68
Interest Coverage-0.02-0.022.44-3.310.72-1.16-3.311.994.85——

ELAN Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio2.172.172.442.751.931.991.652.902.583.363.15
Quick Ratio1.081.081.251.351.021.160.891.621.551.681.73
Cash Ratio0.340.340.360.280.200.390.240.410.490.510.42
Asset Turnover—0.350.350.310.280.290.190.340.340.320.36
Inventory Turnover1.531.531.611.431.591.961.281.591.761.611.80
Days Sales Outstanding—72.7772.8583.4682.9178.76120.09105.7784.4376.0479.01

ELAN Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield——5.6%————0.6%0.9%——
FCF Yield3.2%2.5%6.5%1.6%4.5%2.1%—0.2%3.6%——
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$496M$497M$492M$488M$487M$441M$370M$314M$356M$356M

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetMixed
Cash FlowImproving
Top Statement Risk

Leverage and thin GAAP profitability

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Forward Multiples Imply Turnaround Pricing

Based on Elanco's reported figures, the forward P/E of 23.66 and forward EV/EBITDA of 11.27 sit well below the trailing EV/EBITDA of 16.28, suggesting the market is pricing in earnings recovery rather than current results.

The trailing P/E of -92.28 is not meaningful given negative GAAP earnings, so investors should anchor on forward and EV-based multiples instead. Relative to Zoetis at 13.88 P/E and 10.78 EV/EBITDA, Elanco trades at a premium on forward earnings, which appears to reflect expectations that the innovation pipeline will restore margin expansion. Whether that premium is justified depends on whether operating margins can move durably above the 6.4% latest-quarter level.

Gross Margin Recovers, Operating Margin Lags

As reported in quarterly statements, gross margin recovered to 56.9% in 2026Q3 from 38.1% in 2024Q4, yet operating margin of 6.4% and net margin of 1.4% indicate that gains have not yet flowed through to bottom-line earnings.

The gap between gross and operating margin suggests a heavy fixed cost base in sales and manufacturing absorbing most of the gross profit recovery. The sharp swings in net margin, including a 35.3% print in 2024Q3, point to non-operating items distorting reported earnings, so operating margin is the more reliable read on earning power. Investors should monitor whether the operating margin can sustain above 8% across consecutive quarters before concluding the margin recovery is structural.

Deleveraging Progress Remains Fragile

Based on Elanco's reported figures, debt-to-equity fell from 0.96 in 2024Q2 to 0.56 in 2026Q3, but EBITDA-based leverage of 44.66x in the latest quarter and interest coverage of 1.41x indicate debt service remains tight.

The D/E improvement is real but partly reflects equity base dynamics, and the quarterly D/EBITDA swings from 8.33x to 44.66x show that earnings volatility, not just debt levels, drives the leverage picture. Interest coverage near 1.4x leaves limited room for an earnings shortfall before debt service becomes a constraint. Investors should watch whether leverage ratios stabilize as quarterly EBITDA normalizes, since the current figures may understate or overstate underlying debt burden.

Current Ratio Adequate, Cash Buffer Thin

According to reported balance sheet data, the current ratio of 2.09 and quick ratio of 1.07 indicate near-term obligations are covered, though cash of $465.0M equals only about 3.5% of total assets.

The quick ratio remaining above 1.0 suggests the liquidity position does not depend heavily on inventory conversion, which is a relative strength in a business carrying substantial manufacturing inventory. However, the low cash share of assets implies limited buffer against a sudden operating shock or a delay in receivables collection. Under severe stress, the position would likely depend on continued working capital inflows that have proven volatile across recent quarters.

Cash Strength May Reflect Timing Effects

Based on reported quarterly figures, operating cash flow of $216.0M in 2026Q3 against net income of $18.0M appears strong, but the recent working capital swing of $239.0M suggests much of the cash conversion may be timing-driven rather than durable.

A 12x cash conversion ratio is unusual and warrants scrutiny, since large working capital releases can flatter a single quarter without reflecting sustainable economics. The DSO of 81 days alongside DPO of 71 days and a cash conversion cycle of 312 days suggests working capital is tied up for long periods, so any reversal in payables timing could reverse recent cash gains. Investors should treat the free cash flow margin of 12.3% as provisional until several quarters show consistent conversion.

Download Financial Ratios Data

Includes 30+ ratios · 10 years · Updated daily

Consensus & Technical Research Suite
Open ELAN Terminal

ELAN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ELAN — Frequently Asked Questions

Quick answers to the most common questions about buying ELAN stock.

What is Elanco Animal Health Incorporated's P/E ratio?

Elanco Animal Health Incorporated's current P/E ratio is -89.1x. The historical average is 98.0x.

What is Elanco Animal Health Incorporated's EV/EBITDA?

Elanco Animal Health Incorporated's current EV/EBITDA is 15.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 18.9x.

What is Elanco Animal Health Incorporated's ROE?

Elanco Animal Health Incorporated's return on equity (ROE) is -3.7%. The historical average is -3.4%.

Is ELAN stock overvalued?

Based on historical data, Elanco Animal Health Incorporated is trading at a P/E of -89.1x. Compare with industry peers and growth rates for a complete picture.

What are Elanco Animal Health Incorporated's profit margins?

Elanco Animal Health Incorporated has 43.5% gross margin and 5.3% operating margin.

How much debt does Elanco Animal Health Incorporated have?

Elanco Animal Health Incorporated's Debt/EBITDA ratio is 4.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.